Last reviewed · How we verify
Liposomal Doxorubicin (liposomal-doxorubicin)
Liposomal Doxorubicin, developed by Pfizer Inc., is a marketed drug used to treat various cancers. It is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the synthesis of macromolecules. Liposomal Doxorubicin is indicated for acute lymphoid leukemia, acute myeloid leukemia, advanced ovarian cancer, Burkitt's lymphoma, and breast carcinoma. Its clinical differentiation lies in its ability to reduce cardiotoxicity compared to conventional doxorubicin. The commercial significance of Liposomal Doxorubicin is its established market presence and revenue generation. However, pipeline developments for similar drugs may impact its market share.
At a glance
| Generic name | liposomal-doxorubicin |
|---|---|
| Sponsor | Pfizer |
| Drug class | doxorubicin |
| Target | 72 kDa type IV collagenase |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Acute lymphoid leukemia
- Acute myeloid leukemia, disease
- Advanced ovarian cancer
- Burkitt's lymphoma
- Carcinoma of breast
- Carcinoma of female breast
- Diffuse non-Hodgkin's lymphoma, large cell
- Follicular non-Hodgkin's lymphoma
- Hodgkin's disease
- Invasive Bladder Malignancy
- Kaposi's sarcoma
- Kaposi's sarcoma associated with AIDS
- Malignant tumor of lung
- Malignant tumor of ovary
- Malignant tumor of thyroid gland
- Metastatic Breast Carcinoma
- Metastatic Gastric Cancer
- Multiple myeloma
- Nephroblastoma
- Neuroblastoma
Common side effects
Drug interactions
- streptozocin
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal Doxorubicin CI brief — competitive landscape report
- Liposomal Doxorubicin updates RSS · CI watch RSS
- Pfizer portfolio CI